Financial conflicts of interest are related to voting patterns at FDA advisory committee meetings

MedGenMed Medscape General Medicine

Volumn 8, Issue 4, 2006, Pages

  Lurie, Peter ^a  

^a Public Citizen Health Research Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; ROFECOXIB; VALDECOXIB;

ADVISORY COMMITTEE; CONFLICT OF INTEREST; DRUG APPROVAL; DRUG INDUSTRY; EDITORIAL; FOOD AND DRUG ADMINISTRATION; INTERPERSONAL COMMUNICATION; PUBLIC HEALTH; UNITED STATES; ECONOMICS; ETHICS; HUMAN; METHODOLOGY; POLITICS;

ADVISORY COMMITTEES; CONFLICT OF INTEREST; DISCLOSURE; DRUG APPROVAL; HUMANS; POLITICS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 33750928247     PISSN: 15310132     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (4)

1. Office of the Inspector General. FDA's Review Process for New Drug Applications: A Management Review. Washington, DC: US Department of Health and Human Services; March 2003. OEI-01-01-00590.
2. Harris G, Berenson A. 10 voters on panel backing pain pills had industry ties. New York Times. February 25, 2005:A1.
3. Steinbrook R. Financial conflicts of interest and the Food and Drug Administration's Advisory Committees. N Engl J Med. 2005;353:116-118.
4. Lurie P, Almeida CM, Stine N, Stine AR, Wolfe SM. Financial conflict of interest disclosure and voting patterns at Food and Drug Administration Drug Advisory Committee meetings. JAMA. 2006;295:1921-1928.